Editorials
Why do cancer drugs get such an easy ride?
BMJ 2015; 350 doi: https://doi.org/10.1136/bmj.h2068 (Published 23 April 2015) Cite this as: BMJ 2015;350:h2068
Related articles
- Research Published: 23 September 2015; BMJ 351 doi:10.1136/bmj.h4633
- Analysis Published: 23 October 2015; BMJ 351 doi:10.1136/bmj.h5542
- Research Published: 18 September 2019; BMJ 366 doi:10.1136/bmj.l5221
See more
- Black women in England are at greater risk of late cancer diagnosis than white womenBMJ January 27, 2023, 380 p211; DOI: https://doi.org/10.1136/bmj.p211
- NHS in England will have one strategy for all major conditions, including cancerBMJ January 25, 2023, 380 p194; DOI: https://doi.org/10.1136/bmj.p194
- When will the world get cancer vaccines?BMJ January 06, 2023, 380 o3041; DOI: https://doi.org/10.1136/bmj.o3041
- Beach nudity spreads skin cancer messageBMJ November 29, 2022, 379 o2882; DOI: https://doi.org/10.1136/bmj.o2882
- Cancer waiting times: “We have our foot on the gas,” says NHS England’s cancer leadBMJ November 24, 2022, 379 o2849; DOI: https://doi.org/10.1136/bmj.o2849
Cited by...
- Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis
- Between January 2009 and April 2016, 134 novel anticancer therapies were approved: what is the level of knowledge concerning the clinical benefit at the time of approval?
- Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999-2014
- Why the drug development pipeline is not delivering better medicines
- The FDA's new clothes
- Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study